| Name | PD-1-IN-17 |
|---|---|
| Synonyms |
2-[[4-Amino-1-[5-(1-amino-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl]-4-oxobutyl]cbamoylamino]-3-hydroxypropanoic acid
PD1IN17,PD 1 IN 17 AUPM170 (S)-2-(3-((S)-4-Amino-1-(5-((1S,2R)-1-amino-2-hydroxypropyl)-1,3,4-oxadiazol-2-yl)-4-oxobutyl)ureido)-3-hydroxypropanoic acid L-Serine, N-[[[(1S)-4-amino-1-[5-[(1S,2R)-1-amino-2-hydroxypropyl]-1,3,4-oxadiazol-2-yl]-4-oxobutyl]amino]carbonyl] PD-1-IN-17 (TFA) (1673-1 free base) |
| Description | PD-1-IN-17 is a programmed cell death- 1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
PD-1[1] |
| References |
| Molecular Formula | C13H22N6O7 |
|---|---|
| Molecular Weight | 374.35 |
| Storage condition | 2-8℃ |